Motif Neurotech, a company specialising in bioelectronics for mental health, has raised $18.75m in a series A funding round. The money will be used to advance clinical development of its DOT microstimulator, a device designed to treat treatment-resistant depression (TRD) by stimulating specific brain circuits. The funding will also help the company enhance the device, scale production and distribution.
Group-IB’s Threat Intelligence and Defence Centre Equip Undergraduates with Sophisticated Cybersecurity Technologies to Boost Threat Analysis and Enhance Cyber Resilience for Campus Start-ups
Hey there from the heart of the San Francisco Bay Area! It’s an absolute pleasure to have you back again for our chat on some
